Third Party Viral Specific T-cells (VSTs)

Description

The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.

Conditions

Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.

Third Party Viral Specific T-cells (VSTs) for Treatment of Viral Infections in Immunocompromised Patients

Third Party Viral Specific T-cells (VSTs)

Condition
Viral Infection
Intervention / Treatment

-

Contacts and Locations

Akron

Akron Children's Hospital, Akron, Ohio, United States, 44308

Cincinnati

University of Cincinnati Medical Center, Cincinnati, Ohio, United States, 45219

Cincinnati

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, 45229

Columbus

The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio, United States, 43210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Immunocompromised patient with evidence of viral infection or reactivation
  • * Age \>1 day
  • * Recipients who have had a stem cell transplant must be at least 21 days after stem cell infusion
  • * Clinical status must allow tapering of steroids to \< 0.5mg/kg prednisone or other steroid equivalent
  • * Must be able to receive CTL infusion in Cincinnati
  • * Informed consent obtained by PI or sub-investigator either in person or by phone
  • * Active acute GVHD grades II-IV
  • * Uncontrolled bacterial or fungal infection
  • * Uncontrolled relapse of malignancy requiring treatment with chemotherapy
  • * Infusion of ATG or alemtuzumab within 2 weeks of VST infusion
  • * Biopsy confirmed acute rejection of solid organ transplant OR empiric treatment of suspected but not confirmed acute rejection of solid organ transplant within the last 30 days

Ages Eligible for Study

2 Days to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Hospital Medical Center, Cincinnati,

Michael Grimley, MD, MD, PRINCIPAL_INVESTIGATOR, Children's Hospital Medical Center, Cincinnati

Study Record Dates

2027-12